Condition: Tuberculous Meningitis · HIV I Infection · Sponsor: ANRS, Emerging Infectious Diseases
Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis meningitis in 3 countries (Brazil, Mozambique, and Zambia).
This description comes directly from the study's public registry record.
Vanessa MACHAULT, PhD · +335 57 57 57 63 · vanessa.machault@u-bordeaux.fr
Olivier MARCY, MD PhD
Always discuss trial participation with your own doctor first.
| Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ | Rio de Janeiro, Brazil | Recruiting |
| Instituto Nacional de Saude | Maputo, Mozambique | Not Yet Recruiting |
| Adult Infectious Diseases Centre, University Teaching Hospital | Lusaka, Zambia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05590455